WST Pengajuan SEC - West Pharmaceutical Services, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	5493007NKRGM1RJQ1P16
CIK	105770

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to West Pharmaceutical Services, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 20, 2025	S-8	As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 Registration No.
August 20, 2025	EX-FILING FEES	CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) WEST PHARMACEUTICAL SERVICES, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) WEST PHARMACEUTICAL SERVICES, INC.
July 24, 2025	EX-99.1	West Announces Second-Quarter 2025 Results and Fourth-Quarter 2025 Dividend, Updates Full-Year 2025 Guidance - Conference Call Scheduled for 8 a.m. EDT Today - Exhibit 99.1 West Announces Second-Quarter 2025 Results and Fourth-Quarter 2025 Dividend, Updates Full-Year 2025 Guidance - Conference Call Scheduled for 8 a.m. EDT Today - Exton, PA, July 24, 2025 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2025 and a fourth-quarter 2025 dividend. Second-Quarter 2025 Summary (comparisons to prior-y
July 24, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEU
July 24, 2025	EX-99.2	1 Second-Quarter 2025 Second Quarter Overall Net Sales $766.5M \| 9.2% Diluted Earnings Per Share: $1.82 Adjusted Diluted Earnings Per Share: $1.84 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, In 1 Second-Quarter 2025 Second Quarter Overall Net Sales $766.5M \| 9.2% Diluted Earnings Per Share: $1.82 Adjusted Diluted Earnings Per Share: $1.84 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. WST Q2 2025 Earnings Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying managem
July 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 24, 2025 WEST PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 24, 2025 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
July 21, 2025	EX-99.1	Investor Contact: Media Contact: John Sweeney, CFA Michele Polinsky Vice President, Investor Relations Vice President, Global Communications +1-484-790-0373 +1-610-594-3054 [email protected] [email protected] West Welcomes Rob pressreleasedatedjuly212 Investor Contact: Media Contact: John Sweeney, CFA Michele Polinsky Vice President, Investor Relations Vice President, Global Communications +1-484-790-0373 +1-610-594-3054 John.
July 21, 2025	EX-10.1	Offer Letter, dated July 11, 2025, between West Pharmaceutical Services, Inc. and Robert McMahon. offerletterdatedjuly1120 530 Herman O. West Drive ● Exton, PA 19341 July 11, 2025 Robert McMahon (Sent via email) RE: Offer Letter – Senior Vice President and Chief Financial Officer Dear Robert: I am pleased to offer you the position of Senior Vice President and Chief Financial Officer for West Pharmaceutical Services, Inc. (the “Company”) reporting to Eric Green, President, CEO and Chair of the
July 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 21, 2025 WEST PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 21, 2025 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
May 21, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jur UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 530 Herman O. West Drive, Exton, PA 19341-1147
May 21, 2025	EX-1.01	Conflict Minerals Report as required by Items 1.01 and 1.02 of Form SD. Exhibit 1.01 West Pharmaceutical Services, Inc. Conflict Minerals Report For the Year Ended December 31, 2024 Company Overview This Conflict Minerals Report (the “Report”) of West Pharmaceutical Services, Inc. (the “Company” or “West”) has been prepared pursuant to Rule 13p-1 (the “Rule”) and Form SD promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period Januar
May 12, 2025	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – May 6, 2025 WEST PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – May 6, 2025 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
May 12, 2025	EX-10.15	Amended and Restated 2016 Omnibus Incentive Compensation Plan westomnibusplan2016resta This document constitutes part of a prospectus covering securities that have been registered under the Securities Act of 1933.
May 8, 2025	EX-5.7	Amended and Restated Articles of Incorporation of West Pharmaceutical Services, Inc., dated May 6, 2025. finalmay2025articlesofin AMENDED AND RESTATED ARTICLES OF INCORPORATION OF WEST PHARMACEUTICAL SERVICES, INC.
May 8, 2025	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – May 6, 2025 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation) (C
April 24, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACE
April 24, 2025	EX-10.1	, 2025 between West Pharmaceutical Services, Inc. and Shane Campbell. shanecampbelloffermateri 530 Herman O. West Drive ● Exton, PA 19341 March 28, 2025 Mr. Shane Campbell (Sent via email) RE: Offer Letter – SVP, Chief Proprietary Segment Officer Dear Shane: I am pleased to offer you the position of Senior Vice President and Chief Proprietary Segment Officer for West Pharmaceutical Services, Inc. (the “Company”) reporting to Eric Green, President, CEO and Chair of t
April 24, 2025	EX-99.1	1 West Announces Leadership Changes Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 -- W finalwstleadershippressr 1 West Announces Leadership Changes Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 - West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, tod
April 24, 2025	EX-99.1	West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, April 24, 2025 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2025 and declared a third-quarter 2025 dividend. First-Quarter 2025 Summary (
April 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 22, 2025 WEST PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 22, 2025 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
April 24, 2025	EX-99.2	1 First-Quarter 2025 First Quarter Overall Net Sales $698.0M \| 0.4% Diluted Earnings Per Share: $1.23 Adjusted Diluted Earnings Per Share: $1.45 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. 1 First-Quarter 2025 First Quarter Overall Net Sales $698.0M \| 0.4% Diluted Earnings Per Share: $1.23 Adjusted Diluted Earnings Per Share: $1.45 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. WST Q1 2025 Earnings Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying managemen
April 24, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 24, 2025 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
April 24, 2025	EX-10.2	Stock Unit Agreement, issued pursuant to the 2016 Omnibus Incentive Compensation Plan. a2025wstpsuagreement 1 PERFORMANCE STOCK UNIT AGREEMENT WEST PHARMACEUTICAL SERVICES, INC.
April 24, 2025	EX-10.1	Form of 2025 Restricted Stock Unit Agreement, issued pursuant to the 2016 Omnibus Incentive Compensation Plan. 1 RESTRICTED STOCK UNIT AGREEMENT WEST PHARMACEUTICAL SERVICES, INC. 2016 OMNIBUS INCENTIVE COMPENSATION PLAN West Pharmaceutical Services, Inc. (the “Company”), pursuant to its 2016 Omnibus Incentive Compensation Plan (the “Plan”), hereby grants to the Participant set forth below, the number of Stock Units below, subject to the vesting and other terms and conditions set forth herein (the “Restric
April 24, 2025	EX-10.3	Agreement, issued pursuant to the 2016 Omnibus Incentive Compensation Plan. ex1032025wststockoptiona 1 STOCK OPTION AGREEMENT WEST PHARMACEUTICAL SERVICES, INC.
April 14, 2025	EX-10.1	Separation Agreement and Release, dated as of April 9, 2025 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release Agreement (“Agreement”) is entered into between CINDY REISS-CLARK (“you”) and West Pharmaceutical Services, Inc.
April 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 9, 2025 WEST PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 9, 2025 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
March 21, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2
March 21, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted
March 11, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted
March 11, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – March 7, 2025 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
February 18, 2025	EX-19	Securities Trading Policy, dated and effective April 15, 2021, and Section 10b5-1 Approved Trading Plan Guidelines, dated and effective February 27, 2023 (incorporated by reference to Exhibit 10.42 to the Company's Form 2024 10-K report filed February 20, 2024). SECURITIES TRADING POLICY Effective 4/15/2021 1.SCOPE OF THIS POLICY This Policy applies to all officers and employees (“Employees”) of West Pharmaceutical Services, Inc. and its subsidiaries worldwide (the “Company” or “West”). This Policy also applies to members of the Board of Directors of the Company (“Directors”). 2.OVERVIEW Trading in the securities of the Company and the companies with whic
February 18, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICA
February 18, 2025	EX-21	Subsidiaries of the Company. Exhibit 21 SUBSIDIARIES OF THE COMPANY State/ Country of Incorporation Stock Ownership West Pharmaceutical Services, Inc.
February 18, 2025	EX-97	Executive Officer Incentive-based Compensation Recovery Policy, dated and effective October 2, 2023 (incorporated by reference to Exhibit 10.41 to the Company's Form 2024 10-K report filed February 20, 2024). WEST PHARMACEUTICAL SERVICES, INC. EXECUTIVE OFFICER INCENTIVE-BASED COMPENSATION RECOVERY POLICY (Effective October 2, 2023) PURPOSE The Board of Directors (the “Board”) of West Pharmaceutical Services, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to adopt this Clawback Policy (the “Policy”), which provides for the recovery of covered incentiv
February 13, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – February 13, 2025 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
February 13, 2025	EX-99.2	1 Fourth-Quarter and Full Year 2024 Results Fourth Quarter Overall Net Sales $748.8M \| 2.3% Diluted Earnings Per Share: $1.78 Adjusted Diluted Earnings Per Share: $1.82 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharm 1 Fourth-Quarter and Full Year 2024 Results Fourth Quarter Overall Net Sales $748.
February 13, 2025	EX-99.1	West Announces Fourth-Quarter and Full-Year 2024 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces Fourth-Quarter and Full-Year 2024 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, February 13, 2025 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2024 and introduced 2025 financial guidance. Fourth Quarter Summary (comparisons to prior-year period) & Full Year 2025 Guidan
December 13, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – December 9, 2024 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
December 11, 2024	EX-99.1	West Elects New Director to the Board Exhibit 99.1 Investor Contact: Media Contact: John Sweeney, CFA Michele Polinsky Vice President, Investor Relations Vice President, Global Communications +1 (484) 790-0373 +1 (610) 594-3054 [email protected] [email protected] West Elects New Director to the Board Exton, Pa., December 11, 2024— West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative sol
December 11, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – December 9, 2024 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
October 24, 2024	EX-99.1	West Announces Third-Quarter 2024 Results, Increases Fiscal Year 2024 Guidance and Declares Fourth-Quarter 2024 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces Third-Quarter 2024 Results, Increases Fiscal Year 2024 Guidance and Declares Fourth-Quarter 2024 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, October 24, 2024 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend. Third-Quarter 2024 Summary (
October 24, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHAR
October 24, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – October 24, 2024 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
October 24, 2024	EX-99.2	1 Third-Quarter 2024 Third Quarter Overall Net Sales $746.9M \| 0.1% Diluted Earnings Per Share: $1.85 Adjusted Diluted Earnings Per Share: $1.85 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. 1 Third-Quarter 2024 Third Quarter Overall Net Sales $746.9M \| 0.1% Diluted Earnings Per Share: $1.85 Adjusted Diluted Earnings Per Share: $1.85 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. WST Q3 2024 Earnings Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying managemen
October 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission October 23, 2024 As filed with the Securities and Exchange Commission October 23, 2024 Registration No.
October 23, 2024	S-8 POS	As filed with the Securities and Exchange Commission October 23, 2024 As filed with the Securities and Exchange Commission October 23, 2024 Registration No.
October 7, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – October 1, 2024 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation
July 25, 2024	EX-99.2	1 Second-Quarter 2024 Second Quarter Overall Net Sales $702.1M \| 6.9% Diluted Earnings Per Share: $1.51 Adjusted Diluted Earnings Per Share: $1.52 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, In westq22024julyfinal 1 Second-Quarter 2024 Second Quarter Overall Net Sales $702.1M \| 6.9% Diluted Earnings Per Share: $1.51 Adjusted Diluted Earnings Per Share: $1.52 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. WST Q2 2024 Earnings Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any
July 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 25, 2024 WEST PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 25, 2024 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
July 25, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEU
July 25, 2024	EX-99.1	West Announces Second-Quarter 2024 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces Second-Quarter 2024 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, July 25, 2024 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance. Second-Quarter 2024 Summary (comparisons to prior-year period) •Net sales of $702.1 million declined 6.9%;
July 25, 2024	EX-3.1	Articles 5, 7, 8 and 9 of our Amended and Restated Articles of Incorporation, effective April 24, 2024, attached hereto as Exhibit 3.1. AMENDED AND RESTATED ARTICLES OF INCORPORATION OF WEST PHARMACEUTICAL SERVICES, INC.
July 8, 2024	EX-10.1	Third Amendment and Incremental Facility Amendment, dated as of July 2, 2024, among the Company, as borrower’s representative, each of the lenders party thereto and Bank of America, N.A., as the administrative Execution Version 13680009v3 THIRD AMENDMENT AND INCREMENTAL FACILITY AMENDMENT THIS THIRD AMENDMENT AND INCREMENTAL FACILITY AMENDMENT (this “Agreement”) is entered into as of July 2, 2024 (the “Incremental 2024 Term Loan Effective Date”) among WEST PHARMACEUTICAL SERVICES, INC.
July 8, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 2, 2024 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation) (
June 26, 2024	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-8036 A. Full title of the plan and
June 26, 2024	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-8036 A. Full title of the plan and
May 22, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jur UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 530 Herman O. West Drive, Exton, PA 19341-1147
May 22, 2024	EX-1.01	Conflict Minerals Report as required by Items 1.01 and 1.02 of Form SD. Exhibit 1.01 West Pharmaceutical Services, Inc. Conflict Minerals Report For the Year Ended December 31, 2023 Company Overview This Conflict Minerals Report (the “Report”) of West Pharmaceutical Services, Inc. (the “Company” or “West”) has been prepared pursuant to Rule 13p-1 (the “Rule”) and Form SD promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period Januar
April 26, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 23, 2024 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
April 25, 2024	EX-99.1	West Announces First-Quarter 2024 Results and Declares Third-Quarter 2024 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces First-Quarter 2024 Results and Declares Third-Quarter 2024 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, April 25, 2024 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2024 and updated full-year 2024 financial guidance. First-Quarter 2024 Summary (comparisons to prior-year period) •Net
April 25, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACE
April 25, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 25, 2024 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
April 25, 2024	EX-10.1	Form of 2024 Stock Option Agreement, Performance Stock Unit Agreement and Restricted Stock Unit Agreement, issued pursuant to the 2016 Omnibus Incentive Compensation Plan 1 FORM OF STOCK OPTION AGREEMENT WEST PHARMACEUTICAL SERVICES, INC. 2016 OMNIBUS INCENTIVE COMPENSATION PLAN West Pharmaceutical Services, Inc. (the “Company”), pursuant to its 2016 Omnibus Incentive Compensation Plan (the “Plan”), hereby grants to the Optionee set forth below, the number of stock options (the “Options”) below, subject to the vesting and other terms and conditions set forth herein
April 25, 2024	EX-99.2	1 First-Quarter 2024 First Quarter Overall Net Sales $695.4M \| 3.0% Diluted Earnings Per Share: $1.55 Adjusted Diluted Earnings Per Share: $1.56 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. 1 First-Quarter 2024 First Quarter Overall Net Sales $695.4M \| 3.0% Diluted Earnings Per Share: $1.55 Adjusted Diluted Earnings Per Share: $1.56 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. WST Q1 2024 Earnings Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying managemen
March 19, 2024	PX14A6G	West Pharmaceutical Services, Inc. (WST) West Pharmaceutical Services, Inc. (WST) Shareholder Alert Voluntary submission by John Chevedden, POB 2673, Redondo Beach, CA 90278 West Pharmaceutical Shareholder since 2020 Important to Vote for all 3 Simple Majority Vote Proposals, Proposals 3, 4 and 6 The reason to vote for all 3 Simple Majority Vote Proposals is that Proposals 3 and 4 are binding proposals that require 80% approval of all We
March 13, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted
March 13, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2
March 1, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted
February 20, 2024	EX-10.42	Securities Trading Policy, dated and effective April 15, 2021, and Section 10b5-1 Approved Trading Plan Guidelines, dated and effective February 27, 2023 SECURITIES TRADING POLICY 1. SCOPE OF THIS POLICY This Policy applies to all officers and employees (“Employees”) of West Pharmaceutical Services, Inc. and its subsidiaries worldwide (the “Company” or “West”). This Policy also applies to members of the Board of Directors of the Company (“Directors”). 2. OVERVIEW Trading in the securities of the Company and the companies with which we do business c
February 20, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICA
February 20, 2024	EX-10.14	Non-Qualified Deferred Compensation Plan for Designated Employees, as amended and restated effective January 1, 2024 WEST PHARMACEUTICAL SERVICES, INC. NON-QUALIFIED DEFERRED COMPENSATION PLAN FOR DESIGNATED EMPLOYEES Effective January 1, 2024 IMPORTANT NOTE This document has not been approved by the Department of Labor, Internal Revenue Service, or any other governmental entity. An adopting Employer must determine whether the Plan is subject to the Federal securities laws and the securities laws of the various
February 20, 2024	EX-21	Subsidiaries of the Company. Exhibit 21 SUBSIDIARIES OF THE COMPANY State/ Country of Incorporation Stock Ownership West Pharmaceutical Services, Inc.
February 20, 2024	EX-10.41	Executive Officer Incentive-based Compensation Recovery Policy, dated and effective October 2, 2023 WEST PHARMACEUTICAL SERVICES, INC. EXECUTIVE OFFICER INCENTIVE-BASED COMPENSATION RECOVERY POLICY (Effective October 2, 2023) PURPOSE The Board of Directors (the “Board”) of West Pharmaceutical Services, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to adopt this Clawback Policy (the “Policy”), which provides for the recovery of covered incentiv
February 15, 2024	EX-99.2	1 Fourth-Quarter 2023 and Full Year Results Fourth Quarter Overall Net Sales $732.0M \| 3.3% Diluted Earnings Per Share: $1.83 Adjusted Diluted Earnings Per Share: $1.83 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharm westq4fyfeb2023final 1 Fourth-Quarter 2023 and Full Year Results Fourth Quarter Overall Net Sales $732.
February 15, 2024	EX-99.1	West Announces Fourth-Quarter and Full-Year 2023 Results - Conference Call Scheduled for 9 a.m. EST Today - Exhibit 99.1 West Announces Fourth-Quarter and Full-Year 2023 Results - Conference Call Scheduled for 9 a.m. EST Today - Exton, PA, February 15, 2024 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2023 and introduced full-year 2024 financial guidance. Fourth-Quarter and Full-Year 2023 Summary (comparisons to prior-year pe
February 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – February 15, 2024 WEST PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – February 15, 2024 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
February 13, 2024	SC 13G/A	WST / West Pharmaceutical Services, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02272-westpharmaceuticalse.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 14)* Name of issuer: West Pharmaceutical Services Inc Title of Class of Securities: Common Stock CUSIP Number: 955306105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropri
November 30, 2023	EX-10.40	Amendment No. 1 to Global Master Supply Agreement, entered into on November 27, 2023, and effective from January 1, 2024 through December 31, 2028, between West Pharmaceutical Services, Inc. and ExxonMobil Product Solutions Company. Exhibit 10.40 [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT N°1 to GLOBAL MASTER SUPPLY AGREEMENT This Amendment N°1 ("Amendment") to the Global Master Supply Agreement ("Agreement") is entered into effect as of January 1, 2024, by and between E
November 30, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – November 27, 2023 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
October 26, 2023	EX-99.2	1 Third-Quarter 2023 Third Quarter Overall Net Sales $747.4M \| 8.8% Diluted Earnings Per Share: $2.14 Adjusted Diluted Earnings Per Share: $2.16 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. 1 Third-Quarter 2023 Third Quarter Overall Net Sales $747.4M \| 8.8% Diluted Earnings Per Share: $2.14 Adjusted Diluted Earnings Per Share: $2.16 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. WST Q3 2023 Earnings Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying managemen
October 26, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – October 26, 2023 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
October 26, 2023	EX-3.2	Articles I and IV of our Bylaws, as amended through October 23, 2023 (incorporated by reference to Exhibit 3.2 to the Company's Form 10-Q report for the quarter ended September 30, 2023, filed October 26, 2023). As Amended through October 23, 2023 WEST PHARMACEUTICAL SERVICES, INC. AMENDED AND RESTATED BYLAWS ARTICLE I SHAREHOLDERS Section 1.Meetings. (a)Annual Meeting. The annual meeting of the shareholders for the election of directors from the nominees for director at such meeting and for other business as may be properly brought before the meeting, in each case, in accordance with the applicable provi
October 26, 2023	EX-99.1	West Announces Third-Quarter 2023 Results, Updates Full-Year 2023 Guidance and Declares Fourth-Quarter 2023 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces Third-Quarter 2023 Results, Updates Full-Year 2023 Guidance and Declares Fourth-Quarter 2023 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, October 26, 2023 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2023, updated full-year 2023 financial guidance and declared a fourth-quarter 2023
October 26, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHAR
September 21, 2023	8-K/A	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 25, 2023 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
July 27, 2023	EX-99.2	1 Second-Quarter 2023 Second Quarter Overall Net Sales $753.8M \| 2.3% Diluted Earnings Per Share: $2.06 Adjusted Diluted Earnings Per Share: $2.11 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, In westq22023final 1 Second-Quarter 2023 Second Quarter Overall Net Sales $753.8M \| 2.3% Diluted Earnings Per Share: $2.06 Adjusted Diluted Earnings Per Share: $2.11 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. WST Q2 2023 Earnings Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any acco
July 27, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEU
July 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 27, 2023 WEST PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 27, 2023 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
July 27, 2023	EX-99.1	West Announces Second-Quarter 2023 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces Second-Quarter 2023 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, July 27, 2023 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2023 and updated full-year 2023 financial guidance. Second-Quarter 2023 Summary (comparisons to prior-year period) •Net sales of $753.8 million declined 2.3%;
June 28, 2023	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-8036 A. Full title of the plan and
June 28, 2023	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-8036 A. Full title of the plan and
May 25, 2023	EX-1.01	Conflict Minerals Report as required by Items 1.01 and 1.02 of Form SD. Exhibit 1.01 West Pharmaceutical Services, Inc. Conflict Minerals Report For the Year Ended December 31, 2022 Company Overview This Conflict Minerals Report (the “Report”) of West Pharmaceutical Services, Inc. (the “Company” or “West”) has been prepared pursuant to Rule 13p-1 (the “Rule”) and Form SD promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period Januar
May 25, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jur UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 530 Herman O. West Drive, Exton, PA 19341-0645
April 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 25, 2023 WEST PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 25, 2023 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
April 27, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACE
April 27, 2023	EX-99.1	West Announces First-Quarter 2023 Results and Declares Third-Quarter 2023 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces First-Quarter 2023 Results and Declares Third-Quarter 2023 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, April 27, 2023 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2023 and updated full-year 2023 financial guidance. First-Quarter 2023 Summary (comparisons to prior-year period) •Net
April 27, 2023	EX-99.2	1 First-Quarter 2023 First Quarter Overall Net Sales $716.6M \| 0.5% Diluted Earnings Per Share: $1.85 Adjusted Diluted Earnings Per Share: $1.98 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. finalwestq12023 1 First-Quarter 2023 First Quarter Overall Net Sales $716.6M \| 0.5% Diluted Earnings Per Share: $1.85 Adjusted Diluted Earnings Per Share: $1.98 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharmaceutical Services, Inc. WST Q1 2023 Earnings Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accomp
April 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 27, 2023 WEST PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 27, 2023 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
March 15, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2
March 15, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted
February 21, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICA
February 21, 2023	EX-21	Subsidiaries of the Company. Exhibit 21 SUBSIDIARIES OF THE COMPANY State/ Country of Incorporation Stock Ownership West Pharmaceutical Services, Inc.
February 16, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – February 15, 2023 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
February 16, 2023	EX-99.2	1 Fourth-Quarter 2022 and Full Year Results Fourth Quarter Overall Net Sales $708.7M \| 3.0% Diluted Earnings Per Share: $1.36 Adjusted Diluted Earnings Per Share: $1.77 Eric M. Green President and Chief Executive Officer Chair of the Board West Pharm 1 Fourth-Quarter 2022 and Full Year Results Fourth Quarter Overall Net Sales $708.
February 16, 2023	EX-99.1	West Announces Fourth-Quarter and Full-Year 2022 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces Fourth-Quarter and Full-Year 2022 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, February 16, 2023 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2022 and introduced full-year 2023 financial guidance. Fourth-Quarter and Full-Year 2022 Summary (comparisons to prior-year pe
February 9, 2023	SC 13G/A	WST / West Pharmaceutical Services Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02241-westpharmaceuticalse.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: West Pharmaceutical Services Inc. Title of Class of Securities: Common Stock CUSIP Number: 955306105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropr
October 27, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHAR
October 27, 2022	EX-99.2	1 Third-Quarter 2022 Third Quarter Overall Net Sales $686.9M \| 2.8% Diluted Earnings Per Share: $1.59 Adjusted Diluted Earnings Per Share: $2.03 Eric M. Green President and Chief Executive Officer, Chair of the Board West Pharmaceutical Services, Inc finalwestq3oct2022 1 Third-Quarter 2022 Third Quarter Overall Net Sales $686.9M \| 2.8% Diluted Earnings Per Share: $1.59 Adjusted Diluted Earnings Per Share: $2.03 Eric M. Green President and Chief Executive Officer, Chair of the Board West Pharmaceutical Services, Inc. WST Q3 2022 Earnings Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any ac
October 27, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – October 27, 2022 WEST PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – October 27, 2022 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
October 27, 2022	EX-99.1	West Announces Third-Quarter 2022 Results, Updates Full-Year 2022 Guidance and Declares Fourth-Quarter 2022 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces Third-Quarter 2022 Results, Updates Full-Year 2022 Guidance and Declares Fourth-Quarter 2022 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, October 27, 2022 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2022 and updated full-year 2022 financial guidance. Third-Quarter 2022 Summary (co
July 28, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEU
July 28, 2022	EX-99.2	1 Second-Quarter 2022 Second Quarter Overall Net Sales $771.3M \| 6.6% Diluted Earnings Per Share: $2.48 Adjusted Diluted Earnings Per Share: $2.47 Eric M. Green President and Chief Executive Officer, Chair of the Board West Pharmaceutical Services, I 1 Second-Quarter 2022 Second Quarter Overall Net Sales $771.3M \| 6.6% Diluted Earnings Per Share: $2.48 Adjusted Diluted Earnings Per Share: $2.47 Eric M. Green President and Chief Executive Officer, Chair of the Board West Pharmaceutical Services, Inc. WST Q2 2022 Earnings Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying manage
July 28, 2022	EX-99.1	West Announces Second-Quarter 2022 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces Second-Quarter 2022 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, July 28, 2022 ? West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2022 and updated full-year 2022 financial guidance. Second-Quarter 2022 Summary (comparisons to prior-year period) ?Net sales of $771.3 million grew 6.6%; org
July 28, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? July 28, 2022 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
July 27, 2022	EX-99.1	West Elects New Director to the Board Exhibit 99.1 Investor Contact: Media Contact: Quintin Lai Michele Polinsky Vice President, Investor Relations Vice President, Global Communications +1-610-594-3318 +1-610-594-3054 [email protected] [email protected] West Elects New Director to the Board Exton, PA, July 27, 2022 ? West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for inje
July 27, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 26, 2022 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
June 23, 2022	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-8036 A. Full title of the plan and
June 23, 2022	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-8036 A. Full title of the plan and
May 26, 2022	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? May 24, 2022 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation) (
May 26, 2022	EX-1.01	Conflict Minerals Report as required by Items 1.01 and 1.02 of Form SD. Exhibit 1.01 West Pharmaceutical Services, Inc. Conflict Minerals Report For the Year Ended December 31, 2021 Company Overview This Conflict Minerals Report (the “Report”) of West Pharmaceutical Services, Inc. (the “Company” or “West”) has been prepared pursuant to Rule 13p-1 (the “Rule”) and Form SD promulgated under the Securities Exchange Act of 1934 for the period from January 1, 2021 to Decem
May 26, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jur UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 530 Herman O. West Drive, Exton, PA 19341-0645
May 12, 2022	EX-99.1	West Announces Executive Leadership Appointments Exhibit 99.1 Investor Contact: Media Contact: Quintin Lai Michele Polinsky Vice President, Investor Relations Vice President, Global Communications +1-610-594-3318 +1-610-594-3054 [email protected] [email protected] West Announces Executive Leadership Appointments Exton, PA, May 12, 2022 ? West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solution
May 12, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? May 12, 2022 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation) (
April 28, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? April 28, 2022 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
April 28, 2022	EX-99.1	West Announces First-Quarter 2022 Results and Declares Third-Quarter 2022 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces First-Quarter 2022 Results and Declares Third-Quarter 2022 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, April 28, 2022 ? West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2022 and updated full-year 2022 financial guidance. First-Quarter 2022 Summary (comparisons to prior-year period) ?Net
April 28, 2022	EX-99.2	1 First-Quarter 2022 First Quarter Overall Net Sales $720.0M \| 7.4% Diluted Earnings Per Share: $2.29 \| 15.1% Adjusted Diluted Earnings Per Share: $2.30\| 12.2% Eric M. Green President and Chief Executive Officer West Pharmaceutical Services, Inc. WST 1 First-Quarter 2022 First Quarter Overall Net Sales $720.0M \| 7.4% Diluted Earnings Per Share: $2.29 \| 15.1% Adjusted Diluted Earnings Per Share: $2.30\| 12.2% Eric M. Green President and Chief Executive Officer West Pharmaceutical Services, Inc. WST Q1 2022 Earnings ?We delivered a solid first-quarter 2022 and remain on track to increase capacity throughout the year to satisfy the growing demand
April 28, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACE
April 14, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 tm223484-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Us
April 14, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A 1 tm223484d2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commissi
April 1, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – March 31, 2022 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
April 1, 2022	EX-10.1	Credit Agreement Second Amendment and Joinder and Assumption Agreement, dated as of March 31, 2022, between West, certain of its subsidiaries, the lenders party thereto from time-to-time, Bank of America, N.A., as Administrative Agent, Swing Line Lender and an Issuing Lender; BOFA Securities, Inc., Wells Fargo Securities, LLC, U.S. Bank National Association, and JPMorgan Chase Bank, N.A., as Joint Lead Arrangers and Joint Bookrunners, and Wells Fargo Bank, National Association, U.S. Bank National Association, and JPMorgan Chase Bank, N.A., as Co-Syndication Agents (incorporated by reference from our Form 8-k, filed April 1, 2022). Execution Version SECOND AMENDMENT AND JOINDER AND ASSUMPTION AGREEMENT Dated as of March 31, 2022 among WEST PHARMACEUTICAL SERVICES, INC.
February 28, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? February 22, 2022 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
February 28, 2022	EX-99.1	West Names President and CEO Eric M. Green as Chair of the Board Paolo Pucci appointed Lead Independent Director as current Chair Patrick Zenner Retires from West Board effective May 24, 2022 Exhibit 99.1 Investor Contact: Media Contact: Quintin Lai Michele Polinsky Vice President, Investor Relations Vice President, Global Communications +1-610-594-3318 +1-610-594-3054 [email protected] [email protected] West Names President and CEO Eric M. Green as Chair of the Board Paolo Pucci appointed Lead Independent Director as current Chair Patrick Zenner Retires from Wes
February 22, 2022	EX-10.9	Employment Agreement dated November 4, 2020, between Kimberly MacKay and us (incorporated by reference to Exhibit 10.9 to the Company's Form 10-K report for the year ended December 31, 2021 filed February 22, 2022). Eric M. Green President and Chief Executive Officer Updated: November 3, 2020 Kimberly MacKay (Sent via email & UPS Overnight) RE: Employment Offer Letter Dear Kim: We are very pleased to confirm our offer of employment to you for the position of Senior Vice President, General Counsel and Corporate Secretary This letter will confirm the entire compensation package to be provided to you upon joinin
February 22, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICA
February 22, 2022	EX-21	Subsidiaries of the Company. Exhibit 21 SUBSIDIARIES OF THE COMPANY State/ Country of Incorporation Stock Ownership West Pharmaceutical Services, Inc.
February 22, 2022	EX-10.10	Employment Agreement dated February 8, 2018, between Silji Abraham and us (incorporated by reference to Exhibit 10.10 to the Company's Form 10-K report for the year ended December 31, 2021 filed February 22, 2022). 2 530 Herman O. West Drive ? Exton, PA 19341 Eric M. Green Phone: (610) 594?3237 President & Chief Executive Officer February 7, 2018 Silji Abraham Via E?Mail RE: Offer Letter Dear Silji: We are very pleased to confirm our offer of employment to you for the position of Chief Digital and Transformation Officer for West Pharmaceutical Services, Inc. (the ?Company?). This letter will confirm the enti
February 17, 2022	EX-99.2	1 Fourth-Quarter 2021 and Full Year Results Full Year Overall Net Sales $2.832B \| 31.9% Diluted Earnings Per Share: $8.67 \| 90% Adjusted Diluted Earnings Per Share: $8.58\| 80% Eric M. Green President and Chief Executive Officer West Pharmaceutical Se 1 Fourth-Quarter 2021 and Full Year Results Full Year Overall Net Sales $2.832B \| 31.9% Diluted Earnings Per Share: $8.67 \| 90% Adjusted Diluted Earnings Per Share: $8.58\| 80% Eric M. Green President and Chief Executive Officer West Pharmaceutical Services, Inc. WST Q4/FY 2021 Earnings ?We had a successful 2021 with record organic sales growth and gross operating margin expansion. Our performance
February 17, 2022	EX-99.1	West Announces Fourth-Quarter and Full-Year 2021 Results - Conference Call Scheduled for 9 a.m. EST Today - Exhibit 99.1 West Announces Fourth-Quarter and Full-Year 2021 Results - Conference Call Scheduled for 9 a.m. EST Today - Exton, PA, February 17, 2022 ? West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2021 and introduced full-year 2022 financial guidance. Fourth-Quarter and Full-Year 2021 Summary (comparisons to prior-year pe
February 17, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? February 17, 2022 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
February 10, 2022	SC 13G/A	WST / West Pharmaceutical Services Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: West Pharmaceutical Services Inc. Title of Class of Securities: Common Stock CUSIP Number: 955306105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Sched
February 4, 2022	SC 13G/A	WST / West Pharmaceutical Services Inc. / FRANKLIN RESOURCES INC Passive Investment west21a3.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 955306105 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* WEST PHARMACEUTICAL SERVICES, INC. (Name of Issuer) Common Stock, par value $0.25 per share (Title of Class of Securities) 955306105 (CUSIP Number) December 31,
October 28, 2021	EX-99.2	1 Third-Quarter 2021 Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities L 1 Third-Quarter 2021 Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain ?forward-looking statements? as that term is defined in the Private Securities Litigation Reform Act of 1995.
October 28, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHAR
October 28, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? October 28, 2021 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
October 28, 2021	EX-99.1	West Announces Third-Quarter 2021 Results and Declares Fourth-Quarter 2021 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces Third-Quarter 2021 Results and Declares Fourth-Quarter 2021 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, October 28, 2021 ? West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2021 and updated full-year 2021 financial guidance. Third-Quarter 2021 Summary (comparisons to prior-year period) ?
October 28, 2021	EX-10.1	LIBOR Transition Amendment to the Credit Agreement, dated as of March 28, 2019, between West, each of the lenders party thereto from time to time, and Bank of America, N.A (incorporated by reference to Exhibit 10.1 to the Company's Form 10-Q report for the quarter ended September 30, 2021, filed October 28, 2021). LIBOR TRANSITION AMENDMENT THIS LIBOR TRANSITION AMENDMENT (this ?Agreement?), dated as of October 26, 2021 (the ?Amendment Effective Date?), is entered into between WEST PHARMACEUTICAL SERVICES, INC.
August 24, 2021	8-K/A	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? August 19, 2021 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
August 24, 2021	EX-99.1	West Elects New Director to the Board Exhibit 99.1 Investor Contact: Media Contact: Quintin Lai Michele Pelkowski Vice President, Investor Relations Vice President, Global Communications +1-610-594-3318 +1-610-594-3054 [email protected] [email protected] West Elects New Director to the Board Exton, PA, August 23, 2021 ? West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for
August 23, 2021	EX-99.1	West Elects New Director to the Board Exhibit 99.1 Investor Contact: Media Contact: Quintin Lai Michele Pelkowski Vice President, Investor Relations Vice President, Global Communications +1-610-594-3318 +1-610-594-3054 [email protected] [email protected] West Elects New Director to the Board Exton, PA, August 23, 2021 ? West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for
August 23, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? August 19, 2021 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation
July 30, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEU
July 29, 2021	EX-99.2	1 Second-Quarter 2021 Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities 1 Second-Quarter 2021 Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain ?forward-looking statements? as that term is defined in the Private Securities Litigation Reform Act of 1995.
July 29, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? July 29, 2021 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
July 29, 2021	EX-99.1	West Announces Second-Quarter 2021 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces Second-Quarter 2021 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, July 29, 2021 ? West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2021 and updated full-year 2021 financial guidance. Second-Quarter 2021 Summary (comparisons to prior-year period) ?Net sales of $723.6 million grew 37.3%; or
June 24, 2021	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-8036 A. Full title of the plan and
June 24, 2021	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-8036 A. Full title of the plan and
May 28, 2021	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jur SD 1 formsd12312020.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 530 Herman O. West D
May 28, 2021	EX-1.01	West Pharmaceutical Services, Inc. Conflict Minerals Report For the Year Ended December 31, 2020 EX-1.01 2 exhibit10112312020.htm EX-1.01 Exhibit 1.01 West Pharmaceutical Services, Inc. Conflict Minerals Report For the Year Ended December 31, 2020 Company Overview This Conflict Minerals Report (the “Report”) of West Pharmaceutical Services, Inc. (the “Company”) has been prepared pursuant to Rule 13p-1 (the “Rule”) and Form SD promulgated under the Securities Exchange Act of 1934 for the perio
May 6, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – May 4, 2021 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation) (C
May 6, 2021	EX-10.36	2016 Omnibus Incentive Compensation Plan, as amended through May 4, 2021 (incorporated by reference from our Form 8-k, filed May 4, 2021). Exhibit 10.36 WEST PHARMACEUTICAL SERVICES, INC. 2016 OMNIBUS INCENTIVE COMPENSATION PLAN AMENDMENT NO. 1 WHEREAS, West Pharmaceutical Services, Inc. (the ?Company?) maintains the 2016 Omnibus Incentive Compensation Plan (the ?Plan?), which was approved by shareholders on May 3, 2016, WHEREAS, Section 21(a) the Plan provides that it can be amended by the Board of Directors of the Company (the ?Boa
April 30, 2021	EX-99.2	1 First-Quarter 2021 Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities L 1 First-Quarter 2021 Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain ?forward-looking statements? as that term is defined in the Private Securities Litigation Reform Act of 1995.
April 30, 2021	EX-99.1	West Announces First-Quarter 2021 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces First-Quarter 2021 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, April 29, 2021 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2021 and updated full-year 2021 financial guidance. First-Quarter 2021 Summary (comparisons to prior-year period) •Net sales of $670.7 million grew 36.5%; orga
April 30, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACE
April 30, 2021	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? April 29, 2021 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
April 29, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? April 29, 2021 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
April 29, 2021	EX-99.2	1 First-Quarter 2021 Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities L 1 First-Quarter 2021 Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain ?forward-looking statements? as that term is defined in the Private Securities Litigation Reform Act of 1995.
April 29, 2021	EX-99.1	West Announces First-Quarter 2021 Results - Conference Call Scheduled for 9 a.m. EDT Today - EX-99.1 2 exh991q12021earningsrelease.htm EX-99.1 Exhibit 99.1 West Announces First-Quarter 2021 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, April 29, 2021 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2021 and updated full-year 2021 financial guidance. First-Quarter 2021 Summary (comparisons to prior-year per
March 24, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
March 24, 2021	DEF 14A	- DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 1, 2021	EX-3.2	Our Bylaws, as amended through February 23, 2021 (incorporated by reference from our Form 8-k, filed March 1, 2021). EX-3.2 2 wpsbylawamendmentsfinalfeb.htm EX-3.2 Exhibit 3.2 As Amended through February 23, 2021 WEST PHARMACEUTICAL SERVICES, INC. BYLAWS ARTICLE I SHAREHOLDERS Section 1.Meetings. (a)Annual Meeting. The annual meeting of the shareholders for the election of directors and for other business shall be held at such time as may be fixed by the board of directors, on the first Thursday of May in each y
March 1, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? February 23, 2021 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
February 23, 2021	EX-4.4	Description of Registered Securities (incorporated by reference to Exhibit 4.4 to the Company's 2020 Form 10-K, filed February 23, 2021). EX-4.4 2 ex44descriptionofregistere.htm EX-4.4 Exhibit 4.4 WEST PHARMACEUTICAL SERVICES, INC. DESCRIPTION OF SECURITIES As of December 31, 2020, the common stock of West Pharmaceutical Services, Inc. (“West” or the “Company”) is registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The summary of the general terms and provisions of the Company’s co
February 23, 2021	EX-21	Subsidiaries of the Company. EX-21 3 ex21listofsubsidiaries2020.htm EX-21 Exhibit 21 SUBSIDIARIES OF THE COMPANY State/ Country of Incorporation Stock Ownership West Pharmaceutical Services, Inc. Pennsylvania Parent Co. Tech Group Europe Limited (dba West) Ireland 100.0 Tech Group Grand Rapids, Inc. (dba West) Delaware 100.0 TGPR Holdings Limited Ireland 100.0 W.P.S.F. Limited England 100.0 WD SG Pte. Ltd. Singapore 100.0 Wes
February 23, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICA
February 18, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) ? February 18, 2021 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
February 18, 2021	EX-99.2	Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act EX-99.2 3 wstq4presentation.htm EX-99.2 Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product development and operational
February 18, 2021	EX-99.1	West Announces Fourth-Quarter and Full-Year 2020 Results - Conference Call Scheduled for 9 a.m. EST Today - EX-99.1 2 exh991q42020earningsreleas.htm EX-99.1 Exhibit 99.1 West Announces Fourth-Quarter and Full-Year 2020 Results - Conference Call Scheduled for 9 a.m. EST Today - Exton, PA, February 18, 2021 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter, full-year 2020 and introduced full-year 2021 financial guidance. Fourth-Quarter and Full-Y
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* SC 13G/A 1 tv02157-westpharmaceuticalse.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: West Pharmaceutical Services Inc. Title of Class of Securities: Common Stock CUSIP Number: 955306105 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropr
February 2, 2021	SC 13G/A	FOR SECTION 13 AND 16 REPORTING OBLIGATIONS west20a2.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 955306105 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* WEST PHARMACEUTICAL SERVICES, INC. (Name of Issuer) Common Stock, par value $0.25 per share (Title of Class of Securities) 955306105 (CUSIP Number) December 31,
December 9, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – December 8, 2020 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
December 9, 2020	EX-99.1	West Announces First-Quarter 2021 Dividend, 2021 Share Repurchase Program and Participation in Upcoming Investor Conference Exhibit 99.1 Investor Contact: Media Contact: Quintin Lai Michele Pelkowski Vice President, Investor Relations Vice President, Global Communications +1-610-594-3318 +1-610-594-3054 [email protected] [email protected] West Announces First-Quarter 2021 Dividend, 2021 Share Repurchase Program and Participation in Upcoming Investor Conference Exton, PA, December 9, 2020 — West
November 9, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – November 9, 2020 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
November 9, 2020	EX-99.1	West Appoints Kimberly Banks MacKay as Senior Vice President General Counsel and Corporate Secretary Exhibit 99.1 Investor Contact: Media Contact: Quintin Lai Michele Pelkowski Vice President, Investor Relations Vice President, Global Communications +1-610-594-3318 +1-610-594-3054 [email protected] [email protected] West Appoints Kimberly Banks MacKay as Senior Vice President General Counsel and Corporate Secretary Exton, Pa., November 9, 2020 – West Pharmaceutical Service
October 28, 2020	EX-99.1	West Announces Increase to Fourth-Quarter 2020 Dividend Exhibit 99.1 Investor Contact: Media Contact: Quintin Lai Michele Pelkowski Vice President, Investor Relations Vice President, Global Communications +1-610-594-3318 +1-610-594-3054 [email protected] [email protected] West Announces Increase to Fourth-Quarter 2020 Dividend Exton, PA, October 28, 2020 — West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innova
October 28, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – October 28, 2020 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
October 23, 2020	EX-10.10	Non-Qualified Deferred Compensation Plan for Designated Employees, as amended and restated effective January 1, 2020 (incorporated by reference to Exhibit 10.10 to the Company's Form 10-Q report for the quarter ended September 30, 2020, filed October 23, 2020). EXHIBIT 10.10 West Pharmaceutical Services, INC. NON-QUALIFIED DEFERRED COMPENSATION PLAN FOR DESIGNATED EMPLOYEES (Amended and Restated Effective as of January 1, 2020, except as otherwise noted herein or required by applicable law) Plan Document THE WEST PHARMACEUTICAL SERVICES, INC. NON-QUALIFIED DEFERRED COMPENSATION PLAN FOR DESIGNATED EMPLOYEES (Amended and Restated Effective January 1, 2020
October 23, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHAR
October 22, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – October 22, 2020 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
October 22, 2020	EX-99.2	Third-Quarter 2020 Results Overall Net Sales OVERALL ORGANIC SALES GROWTH $548M \| 20.1% Proprietary Products Q3 2020 organic sales Q3 growth of 20.3%, led by sales of high-value 18.2% Diluted Earnings Per Share: $1.09 \| 45% products, which grew doubl wstq32020presentation Third-Quarter 2020 Results Overall Net Sales OVERALL ORGANIC SALES GROWTH $548M \| 20.
October 22, 2020	EX-99.1	West Announces Third-Quarter 2020 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces Third-Quarter 2020 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, October 22, 2020 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2020 and updated full-year 2020 financial guidance. Third-Quarter 2020 Summary (comparisons to prior-year period) •Net sales of $548.0 million grew 20.1%; or
July 24, 2020	EX-3.1	Article 5, 6, 8(c) and 9 of our Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Company's Form 10-Q report for the quarter ended June 30, 2020, filed July 24, 2020). EXHIBIT 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF WEST PHARMACEUTICAL SERVICES, INC. (Effective as of May 5, 2020) 1. The name of the Corporation is West Pharmaceutical Services, Inc. 2. The location and post office address of the Corporation’s registered office in Pennsylvania is c/o Corporation Service Company, 2595 Interstate Drive, Suite 103, Harrisburg, PA 17110. 3. The Corporatio
July 24, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEU
July 23, 2020	EX-99.1	West Announces Second-Quarter 2020 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces Second-Quarter 2020 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, July 23, 2020 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2020 and updated full-year 2020 financial guidance. Second-Quarter 2020 Summary (comparisons to prior-year period) •Net sales of $527.2 million grew 12.2%; or
July 23, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 23, 2020 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
July 23, 2020	EX-99.2	West Pharmaceutical Services, Inc. Second-Quarter 2020 Analyst Conference Call 9 a.m. Eastern Time, July 23, 2020 Eric M. Green Bernard J. Birkett Speakers President and Senior Vice President and Chief Executive Officer Chief Financial Officer A webc EX-99.2 3 wstq22020presentation072.htm EX-99.2 West Pharmaceutical Services, Inc. Second-Quarter 2020 Analyst Conference Call 9 a.m. Eastern Time, July 23, 2020 Eric M. Green Bernard J. Birkett Speakers President and Senior Vice President and Chief Executive Officer Chief Financial Officer A webcast of today’s call can be accessed in the “Investors” section of the Company’s website: www.westpharma
July 15, 2020	EX-99.1	West Announces Third Quarter 2020 Dividend Exhibit 99.1 Investor Contact: Media Contact: Quintin Lai Michele Pelkowski Vice President, Investor Relations Sr. Director, Global Communications +1-610-594-3318 +1-610-594-3054 [email protected] [email protected] West Announces Third Quarter 2020 Dividend Exton, PA, July 15, 2020 — West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for
July 15, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 15, 2020 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
June 19, 2020	11-K	- 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-8036 A. Full title of the plan and
June 19, 2020	11-K	- 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-8036 A. Full title of the plan and
May 28, 2020	EX-1.01	West Pharmaceutical Services, Inc. Conflict Minerals Report For the Year Ended December 31, 2019 Exhibit 1.01 West Pharmaceutical Services, Inc. Conflict Minerals Report For the Year Ended December 31, 2019 Company Overview This Conflict Minerals Report (the “Report”) of West Pharmaceutical Services, Inc. (the “Company”) has been prepared pursuant to Rule 13p-1 (the “Rule”) and Form SD promulgated under the Securities Exchange Act of 1934 for the period from January 1, 2019 to December 31, 20
May 28, 2020	SD	- SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 530 Herman O. West Drive, Exton, PA 19341-0645
May 7, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – May 5, 2020 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation) (C
April 24, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACE
April 23, 2020	EX-99.1	West Announces First-Quarter 2020 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exhibit 99.1 West Announces First-Quarter 2020 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, April 23, 2020 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2020 and updated full-year 2020 financial guidance. First-Quarter 2020 Summary (comparisons to prior-year period) •Net sales of $491.5 million grew 10.8%; orga
April 23, 2020	EX-99.2	West Pharmaceutical Services, Inc. First-Quarter 2020 Analyst Conference Call 9 a.m. Eastern Time, April 23, 2020 Eric M. Green Bernard J. Birkett Speakers President and Senior Vice President and Chief Executive Officer Chief Financial Officer A webc wstq12020presentation West Pharmaceutical Services, Inc. First-Quarter 2020 Analyst Conference Call 9 a.m. Eastern Time, April 23, 2020 Eric M. Green Bernard J. Birkett Speakers President and Senior Vice President and Chief Executive Officer Chief Financial Officer A webcast of today’s call can be accessed in the “Investors” section of the Company’s website: www.westpharma.com 877-930-8295 (U.S.)
April 23, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – April 23, 2020 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
April 17, 2020	DEFA14A	WST / West Pharmaceutical Services, Inc. DEFA14A - - DEFA14A DEFA14A 1 a20-162071defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (a
March 25, 2020	DEFA14A	WST / West Pharmaceutical Services, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
March 25, 2020	DEF 14A	WST / West Pharmaceutical Services, Inc. DEF 14A - - DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 13, 2020	PRE 14A	WST / West Pharmaceutical Services, Inc. PRE 14A - - PRE 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 24, 2020	EX-10.2	First Amendment and Incremental Facility Amendment, dated as of December 30, 2019, between West, each of the lenders party thereto from time to time, and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.2 to the Company's 2019 10-K file February 24, 2020). EX-10.2 3 ex102firstamendmentand.htm EX-10.2 Exhibit 10.2 FIRST AMENDMENT AND INCREMENTAL FACILITY AMENDMENT THIS FIRST AMENDMENT AND INCREMENTAL FACILITY AMENDMENT (this “Agreement”) is entered into as of December 30, 2019 (the “Incremental Term Loan Effective Date”) among WEST PHARMACEUTICAL SERVICES, INC., a Pennsylvania corporation (the “Company” or “Borrowers’ Representative”), each of the Le
February 24, 2020	EX-21	Subsidiaries of the Company. Exhibit 21 SUBSIDIARIES OF THE COMPANY Jurisdiction of Incorporation Stock Ownership West Pharmaceutical Services, Inc.
February 24, 2020	EX-4.4	Description of Registered Securities. Exhibit 4.4 WEST PHARMACEUTICAL SERVICES, INC. DESCRIPTION OF SECURITIES As of December 31, 2019, the common stock of West Pharmaceutical Services, Inc. (“West” or the “Company”) is registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The summary of the general terms and provisions of the Company’s common stock set forth below does not purport to
February 24, 2020	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICA
February 18, 2020	EX-99.1	West Elects New Director to the Board Exhibit 99.1 Investor Contact: Media Contact: Quintin Lai Emily Denney Vice President, Investor Relations Vice President, Global Communications +1-610-594-3318 +1-610-594-3035 [email protected] [email protected] West Elects New Director to the Board Exton, PA, February 17, 2020 – West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectab
February 18, 2020	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – February 17, 2020 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
February 13, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – February 13, 2020 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
February 13, 2020	EX-99.2	West Pharmaceutical Services, Inc. Fourth Quarter 2019 Analyst Conference Call 9 a.m. Eastern Time, February 13, 2020 ▪ A webcast of today’s call can be accessed in the “Investors” section of the Company’s website: www.westpharma.com Speakers: ▪ To p wstq42019presentation West Pharmaceutical Services, Inc. Fourth Quarter 2019 Analyst Conference Call 9 a.m. Eastern Time, February 13, 2020 ▪ A webcast of today’s call can be accessed in the “Investors” section of the Company’s website: www.westpharma.com Speakers: ▪ To participate on the call, please dial: Eric M. Green − 877-930-8295 (U.S.) President and Chief Executive Officer − 253-336-8738 (I
February 13, 2020	EX-99.1	West Announces Fourth-Quarter and Full-Year 2019 Results - Conference Call Scheduled for 9 a.m. EST Today - Exhibit 99.1 West Announces Fourth-Quarter and Full-Year 2019 Results - Conference Call Scheduled for 9 a.m. EST Today - Exton, PA, February 13, 2020 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2019 and introduced full-year 2020 financial guidance. Fourth-Quarter and Full-Year 2019 Summary (comparisons to prior-year pe
February 12, 2020	SC 13G/A	WST / West Pharmaceutical Services, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: West Pharmaceutical Services Inc Title of Class of Securities: Common Stock CUSIP Number: 955306105 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedu
February 5, 2020	SC 13G/A	WST / West Pharmaceutical Services, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 west19a1.htm CUSIP NO. 955306105 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* WEST PHARMACEUTICAL SERVICES, INC. (Name of Issuer) Common Stock, par value $.25 per share (Title of Class of Securities) 955306105 (CUSIP Number) December 31, 2019 (Date of Event Which Require
January 16, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – January 10, 2020 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
January 16, 2020	EX-10.1	Global Master Supply Agreement by and between ExxonMobil Chemical Company and us, entered into on January 10, 2020, and effective January 1, 2019 through December 31, 2023 (incorporated by reference to Exhibit 10.1 to the Company's Form 8-K report filed January 16, 2020). Exhibit 10.1 [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. GLOBAL MASTER SUPPLY AGREEMENT This Global Master Supply Agreement ("Agreement" or "Contract") is between ExxonMobil Chemical Company, a division of Exxon Mobil Corporation ("Seller"),on behalf of
December 13, 2019	EX-99.1	West Announces First-Quarter Dividend, Share Repurchase Program and Participation in Upcoming Investor Conference Exhibit 99.1 Investor Contact: Media Contact: Quintin Lai Emily Denney Vice President, Investor Relations Vice President, Global Communications +1-610-594-3318 +1-610-594-3035 [email protected] [email protected] West Announces First-Quarter Dividend, Share Repurchase Program and Participation in Upcoming Investor Conference EXTON, PA, – December 13, 2019 – West Pharmaceutical Se
December 13, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – December 10, 2019 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
November 21, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – November 19, 2019 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
October 29, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHAR
October 24, 2019	EX-99.2	West Pharmaceutical Services, Inc. Third-Quarter 2019 Analyst Conference Call 9 a.m. Eastern Time, October 24, 2019 ▪ A webcast of today’s call can be accessed in the “Investors” section of the Company’s website: www.westpharma.com Speakers: ▪ To par q32019wstpresentation West Pharmaceutical Services, Inc. Third-Quarter 2019 Analyst Conference Call 9 a.m. Eastern Time, October 24, 2019 ▪ A webcast of today’s call can be accessed in the “Investors” section of the Company’s website: www.westpharma.com Speakers: ▪ To participate on the call, please dial: Eric M. Green − 877-930-8295 (U.S.) President and Chief Executive Officer − 253-336-8738 (Int
October 24, 2019	EX-99.1	West Announces Third-Quarter 2019 Results - Conference Call Scheduled for 9 a.m. EDT Today - EX-99.1 2 exh991q32019earningsre.htm EXHIBIT 99.1 Exhibit 99.1 West Announces Third-Quarter 2019 Results - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, October 24, 2019 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2019 and updated full-year 2019 financial guidance. Third-Quarter 2019 Summary (comparisons to prior-year p
October 24, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – October 24, 2019 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
October 16, 2019	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – October 15, 2019 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporatio
October 16, 2019	EX-10.1	Amendment Agreement, dated as of October 15, 2019, between us and Daikyo Seiko, Ltd., (incorporated by reference to Exhibit 10.1 to the Company's Form 8-K filed October 16, 2019). Exhibit 10.1 [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT AGREEMENT This Amendment Agreement, is made and entered into this 15th day of October 2019 by and between Daikyo Seiko, Ltd., a corporation organized and existing under the laws of Japan
October 16, 2019	EX-99.1	West Increases Equity Stake in Daikyo Seiko, Ltd. - Extending the Companies’ Longstanding Partnership in Injectable Drug Delivery Exhibit 99.1 Investor Relations Contact: Media Contact: Quintin Lai Emily Denney Investor Relations, West Global Communications, West +1-610-594-3318 +1-610-594-3035 [email protected] [email protected] West Increases Equity Stake in Daikyo Seiko, Ltd. - Extending the Companies’ Longstanding Partnership in Injectable Drug Delivery Exton, PA - October 16, 2019 - West Pharmaceutica
October 2, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – September 27, 2019 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporat
September 4, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – September 4, 2019 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporati
September 4, 2019	EX-99.1	West Pharmaceutical Services, Inc. September 2019 Investor Presentation Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forwar sep2019wstpresentation West Pharmaceutical Services, Inc. September 2019 Investor Presentation Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include,
July 29, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEU
July 25, 2019	EX-99.2	West Pharmaceutical Services, Inc. Second-Quarter 2019 Analyst Conference Call 9 a.m. Eastern Time, July 25, 2019 ▪ A webcast of today’s call can be accessed in the “Investors” section of the Company’s website: www.westpharma.com Speakers: ▪ To parti q22019wstpresentation West Pharmaceutical Services, Inc. Second-Quarter 2019 Analyst Conference Call 9 a.m. Eastern Time, July 25, 2019 ▪ A webcast of today’s call can be accessed in the “Investors” section of the Company’s website: www.westpharma.com Speakers: ▪ To participate on the call, please dial: Eric M. Green − 877-930-8295 (U.S.) President and Chief Executive Officer − 253-336-8738 (Inter
July 25, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – July 25, 2019 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation)
July 25, 2019	EX-99.1	West Announces Second-Quarter 2019 Results and Announces an Increase to Fourth-Quarter 2019 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - EX-99.1 2 exh991q22019earningsrelease.htm EXHIBIT 99.1 Exhibit 99.1 West Announces Second-Quarter 2019 Results and Announces an Increase to Fourth-Quarter 2019 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, July 25, 2019 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2019 and updated full-year 2019 financial gui
June 21, 2019	11-K	WST / West Pharmaceutical Services, Inc. 11-K - - 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-8036 A. Full title of the plan and
June 21, 2019	11-K	WST / West Pharmaceutical Services, Inc. 11-K - - 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-8036 A. Full title of the plan and
May 30, 2019	EX-1.01	West Pharmaceutical Services, Inc. Conflict Minerals Report For the Year Ended December 31, 2018 Exhibit 1.01 West Pharmaceutical Services, Inc. Conflict Minerals Report For the Year Ended December 31, 2018 Company Overview This Conflict Minerals Report (the “Report”) of West Pharmaceutical Services, Inc. (the “Company”) has been prepared pursuant to Rule 13p-1 (the “Rule”) and Form SD promulgated under the Securities Exchange Act of 1934 for the period from January 1, 2018 to December 31, 20
May 30, 2019	SD	WST / West Pharmaceutical Services, Inc. SD - - FORM SD_2018 SD 1 formsd12312018.htm FORM SD2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 530 Herman
May 14, 2019	EX-99.1	West Pharmaceutical Services, Inc. Spring 2019 Investor Presentation Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-l mayjune2019wstpresentati West Pharmaceutical Services, Inc. Spring 2019 Investor Presentation Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include,
May 14, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) – May 14, 2019 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-8036 23-1210010 (State or other jurisdiction of incorporation) (
May 10, 2019	SC 13G/A	WST / West Pharmaceutical Services, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0017-westpharmaceuticalser.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: West Pharmaceutical Services Inc Title of Class of Securities: Common Stock CUSIP Number: 955306105 Date of Event Which Requires Filing of this Statement: April 30, 2019 Check the appropriate
May 8, 2019	EX-10.2	Form of 2019 Performance Stock Unit (PSU) Award issued under the 2016 Omnibus Incentive Compensation Plan (incorporated by reference to Exhibit 10.2 to the Company's Form 10-Q report for the quarter ended March 31, 2019, filed May 8, 2019). EX-10.2 2 ex1022019psuawardagreement.htm EXHIBIT 10.2 Performance Stock Unit (PSU) Award Agreement On <>, West Pharmaceutical Services granted <> a performance stock unit award (PSU) of <> PSUs based on target achievement. The award is granted under the terms of the West 2016 Omnibus Incentive Compensation Plan (the “Plan”). The terms and conditions of the award follows. Signed for and on behalf o

GB:0ADY
MX:WST
DE:WPS	€ 210.60
IT:1WST	€ 210.40

WST / West Pharmaceutical Services, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings